Cutaneous follicle center lymphoma, unspecified site
ICD-10 C82.60 is a billable code used to indicate a diagnosis of cutaneous follicle center lymphoma, unspecified site.
Cutaneous follicle center lymphoma (CFCL) is a type of non-Hodgkin lymphoma that primarily affects the skin. It arises from B-cells in the follicle center of lymphoid tissue and is characterized by the presence of neoplastic follicle center cells in the skin. Patients may present with various skin lesions, including plaques, nodules, or tumors, which can be mistaken for other dermatological conditions. The disease is typically indolent, but it can transform into a more aggressive form. Diagnosis is confirmed through skin biopsy, which reveals atypical lymphoid cells. Staging of CFCL is crucial for determining prognosis and treatment options, often utilizing the Ann Arbor staging system. B-symptoms, such as fever, night sweats, and weight loss, may or may not be present, influencing treatment decisions. Treatment protocols may include topical therapies, radiation, and systemic therapies such as chemotherapy or immunotherapy, depending on the extent of the disease and patient factors.
Detailed descriptions of skin lesions, biopsy results, and treatment plans.
Patients presenting with skin lesions that may be mistaken for other dermatological conditions.
Ensure accurate descriptions of lesion characteristics and locations to support coding.
Comprehensive staging information, treatment protocols, and follow-up care details.
Management of patients with confirmed CFCL requiring systemic therapy.
Document any transformation to aggressive lymphoma and associated treatment changes.
Used when a biopsy is performed to confirm CFCL.
Include detailed pathology report and clinical notes.
Dermatology and oncology must ensure accurate reporting of biopsy results.
Common treatments include topical therapies, radiation therapy, and systemic treatments such as chemotherapy or immunotherapy, depending on the stage and extent of the disease.
Diagnosis is typically made through a skin biopsy, which reveals atypical follicle center cells. Clinical evaluation and staging are also essential.
